evipedia.ai
← Back

Sarcosine for Health & Longevity

Created on 11/03/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Sarcosine, a glycine-derived supplement studied for mental illness and aging, increases glycine at a learning- and mood-related brain receptor. Small trials support improved low mood and, added to most psychosis medicines, schizophrenia symptoms, though reviews disagree. Longevity appeal rests on animal research, untested in humans. Short-term safety looks reassuring; open questions: rare mood over-activation with certain antidepressants, possible mild hemoglobin drop seen with related drugs, and laboratory prostate cancer spread. (Full Review)

Protocol

Standard dose
2 g/day
Used in every trial of an independent meta-analysis; weight-based alternative 30 mg/kg/day
Single or split dose
1 g twice daily
With or without food; half-life about 1 hour
Time of day
Morning and evening
No study compared timing; no trial reported sleep disruption
Time to effect
Schizophrenia symptoms
Over 6 weeks
Trial period for psychiatric improvement; no time course exists for aging-related outcomes
Low mood
Faster remission than citalopram
Sarcosine as sole treatment
Obsessive-compulsive symptoms
By week 4
Early responders

Benefits

Contraindications
  • Bipolar disorder or prior hypomania or mania
  • Men with diagnosed prostate cancer, including active surveillance
  • Pregnancy and breastfeeding
  • Anemia
    •
Key Interactions
  • Clozapine: no benefit; no harmful interaction found
  • SSRIs (citalopram, sertraline) and SNRIs (venlafaxine): irritability or hypomania
  • Sodium benzoate: additive cognitive effect
    •
Theoretical (inferred from mechanism)
  • Glycine-site agonists (glycine, D-serine, D-cycloserine): additive receptor stimulation; possible irritability or over-activation
  • Synthetic GlyT1 inhibitors (bitopertin, iclepertin): additive glycine elevation and greater hemoglobin reduction
  • NMDA antagonists (ketamine, dextromethorphan): may blunt either agent's effect
  • Methyl-donor and choline-pathway supplements (betaine, choline, SAMe): higher sarcosine load of unknown consequence
    •

Risk & Side Effects

  • High:
  • Medium:
  • Low: Mood elevation and irritability with serotonergic antidepressants; headache and dizziness; lower hemoglobin; prostate cancer progression
    •
  • Speculative: Suppressed breathing rhythm at high glycine exposure
    •

Monitoring

Marker Target Why
Hemoglobin Men 13.5–17.5 g/dL; women 12.0–15.5 g/dL Safety check: related drugs lower hemoglobin
PSA (men) Below 4.0 ng/mL Safety check: laboratory prostate cancer invasion data
Plasma glycine About 120–470 nmol/mL A rise from own baseline confirms biological effect
Plasma sarcosine 0–4 nmol/mL Confirms absorption and adherence

Cadence: Baseline, then at 4 weeks, at 3 months, then every 6–12 months during continued use; mood, irritability and sleep need weekly in the first 3 months; no change after 8–12 weeks at 2 g/day suggests non-response

Qualitative Assessment

  • Mood and drive: lift in low mood, with attention to irritability or reduced sleep need
  • Mental clarity: day-to-day focus and memory
  • Energy and recovery: perceived energy and training recovery
  • Sleep quality: duration and continuity
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.